DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review

April 2021 | 56 pages | ID: D7A8EF48167EN
GlobalData

Abstracts

DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

DURECT Corp (Durect) is a biopharmaceutical company that focuses on research and development of new chemical entities for the treatment of acute organ injury and chronic liver diseases based on its endogenous epigenetic regulator program. The company’s major product pipeline comprises DUR-928, indicated for the treatment of alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, indicated to treat post-operative pain; and Oradur, indicated for chronic pain and attention deficit hyperactivity disorders. It also manufactures and sells osmotic pumps for laboratory research; and offers standard and custom biodegradable polymers and excipients for customers in pharmaceutical and medical device industry. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in Cupertino, California, the US.

DURECT Corp Key Recent Developments

Mar 05,2021: DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs
Feb 25,2021: DURECT to Announce 2020 Financial Results and Provide Business Update on March 4
Jan 04,2021: DURECT announces closing of LACTEL Absorbable Polymer Product Line sale to Evonik and receipt of $15 million
Nov 02,2020: DURECT announces third quarter 2020 financial results and update of programs
Nov 02,2020: DURECT appoints Dr. Norman Sussman as Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

DURECT Corp - Key Facts
DURECT Corp - Key Employees
DURECT Corp - Key Employee Biographies
DURECT Corp - Major Products and Services
DURECT Corp - History
DURECT Corp - Company Statement
DURECT Corp - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
DURECT Corp - Business Description
Geographical Segment: Europe
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
DURECT Corp - Corporate Strategy
DURECT Corp - SWOT Analysis
SWOT Analysis - Overview
DURECT Corp - Strengths
DURECT Corp - Weaknesses
DURECT Corp - Opportunities
DURECT Corp - Threats
DURECT Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

DURECT Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
DURECT Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
DURECT Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 05, 2021: DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs
Feb 25, 2021: DURECT to Announce 2020 Financial Results and Provide Business Update on March
Nov 02, 2020: DURECT announces third quarter 2020 financial results and update of programs
Nov 02, 2020: DURECT appoints Dr. Norman Sussman as Chief Medical Officer
Aug 03, 2020: DURECT announces second quarter 2020 financial results and update of programs
May 12, 2020: DURECT announces first quarter 2020 financial results and update of programs
May 05, 2020: DURECT receives loan under Paycheck Protection Program
Mar 03, 2020: DURECT announces fourth quarter and full year 2019 financial results and update of programs

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

DURECT Corp, Key Facts
DURECT Corp, Key Employees
DURECT Corp, Key Employee Biographies
DURECT Corp, Major Products and Services
DURECT Corp, History
DURECT Corp, Key Competitors
DURECT Corp, Ratios based on current share price
DURECT Corp, Annual Ratios
DURECT Corp, Annual Ratios (Cont...1)
DURECT Corp, Interim Ratios
DURECT Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
DURECT Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
DURECT Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

DURECT Corp, Performance Chart (2016 - 2020)
DURECT Corp, Ratio Charts
DURECT Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
DURECT Corp, Medical Equipment, Deals by Type, 2015 to YTD 2021